HDAC inhibitors and neurodegeneration: At the edge between protection and damage

Pharmacological Research

Volumn 62, Issue 1, 2010, Pages 11-17

  Dietz, Karen C ^a   Casaccia, Patrizia ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Brain; Chromatin; Epigenetics; Myelin; Neurological disorders

Indexed keywords

BUTYRIC ACID; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; RESVERATROL; SIRTUIN; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ASTROCYTE; CELL PROTECTION; CELL SURVIVAL; CELL TYPE; DRUG ACTIVITY; ENZYME INHIBITION; LONGEVITY; LYMPHOCYTE; MICROGLIA; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REVIEW;

ANIMALS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEURODEGENERATIVE DISEASES; NEUROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 77952875979     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.01.011     Document Type: Review

References (91)

1. Langley B., Brochier C., Rivieccio M.A. Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke. Stroke 2009, 40:2899-2905.
2. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
3. Lawless M.W., Norris S., O'Byrne K.J., Gray S.G. Targeting histone deacetylases for the treatment of disease. J Cell Mol Med 2009, 13:826-852.
4. Kazantsev A.G., Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008, 7:854-868.
5. Morrison B.E., Majdzadeh N., D'Mello S.R. Histone deacetylases: focus on the nervous system. Cell Mol Life Sci 2007, 64:2258-2269.
6. Hahnen E., Hauke J., Trankle C., Eyupoglu I.Y., Wirth B., Blumcke I. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin Invest Drugs 2008, 17:169-184.
7. Thiagalingam S., Cheng K.H., Lee H.J., Mineva N., Thiagalingam A., Ponte J.F. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci 2003, 983:84-100.
8. Khochbin S., Verdel A., Lemercier C., Seigneurin-Berny D. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 2001, 11:162-166.
9. Wang A.H., Yang X.J. Histone deacetylase 4 possesses intrinsic nuclear import and export signals. Mol Cell Biol 2001, 21:5992-6005.
10. Taylor D.M., Maxwell M.M., Luthi-Carter R., Kazantsev A.G. Biological and potential therapeutic roles of sirtuin deacetylases. Cell Mol Life Sci 2008, 65:4000-4018.
11. Finkel T., Deng C.X., Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009, 460:587-591.
12. Anekonda T.S., Reddy P.H. Neuronal protection by sirtuins in Alzheimer's disease. J Neurochem 2006, 96:305-313.
13. Glozak M.A., Sengupta N., Zhang X., Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23.
14. Spange S., Wagner T., Heinzel T., Kramer O.H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009, 41:185-198.
15. Saha R.N., Pahan K., HATs HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ 2006, 13:539-550.
16. Kim H.J., Rowe M., Ren M., Hong J.S., Chen P.S., Chuang D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007, 321:892-901.
17. Faraco G., Pancani T., Formentini L., Mascagni P., Fossati G., Leoni F., et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol 2006, 70:1876-1884.
18. Graham B., Gibson S.B. The two faces of NFkappaB in cell survival responses. Cell Cycle 2005, 4:1342-1345.
19. Halili M.A., Andrews M.R., Sweet M.J., Fairlie D.P. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 2009, 9:309-319.
20. Bieliauskas A.V., Pflum M.K. Isoform-selective histone deacetylase inhibitors. Chem Soc Rev 2008, 37:1402-1413.
21. Thomas E.A. Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors. Mol Neurobiol 2009, 40:33-45.
22. Simonini M.V., Camargo L.M., Dong E., Maloku E., Veldic M., Costa E., et al. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci USA 2006, 103:1587-1592.
23. Guarente L. Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol 2007, 72:483-488.
24. Qin W., Yang T., Ho L., Zhao Z., Wang J., Chen L., et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 2006, 281:21745-21754.
25. Pallas M., Pizarro J.G., Gutierrez-Cuesta J., Crespo-Biel N., Alvira D., Tajes M., et al. Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. Neuroscience 2008, 154:1388-1397.
26. Kim D., Nguyen M.D., Dobbin M.M., Fischer A., Sananbenesi F., Rodgers J.T., et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007, 26:3169-3179.
27. Kakefuda K., Fujita Y., Oyagi A., Hyakkoku K., Kojima T., Umemura K., et al. Sirtuin 1 overexpression mice show a reference memory deficit, but not neuroprotection. Biochem Biophys Res Commun 2009, 387:784-788.
28. Liu D., Gharavi R., Pitta M., Gleichmann M., Mattson M.P. Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons. Neuromol Med 2009, 11:28-42.
29. Prozorovski T., Schulze-Topphoff U., Glumm R., Baumgart J., Schroter F., Ninnemann O., et al. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat Cell Biol 2008, 10:385-394.
30. Green K.N., Steffan J.S., Martinez-Coria H., Sun X., Schreiber S.S., Thompson L.M., et al. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci 2008, 28:11500-11510.
31. Pfister J.A., Ma C., Morrison B.E., D'Mello S.R. Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PLoS One 2008, 3:e4090.
32. Chuang D.M., Leng Y., Marinova Z., Kim H.J., Chiu C.T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 2009, 32:591-601.
33. Li Y., Yuan Z., Liu B., Sailhamer E.A., Shults C., Velmahos G.C., et al. Prevention of hypoxia-induced neuronal apoptosis through histone deacetylase inhibition. J Trauma 2008, 64:863-870. [discussion 70-1].
34. Bolger T.A., Yao T.P. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J Neurosci 2005, 25:9544-9553.
35. Ryu H., Lee J., Olofsson B.A., Mwidau A., Dedeoglu A., Escudero M., et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci USA 2003, 100:4281-4286.
36. Salminen A., Tapiola T., Korhonen P., Suuronen T. Neuronal apoptosis induced by histone deacetylase inhibitors. Brain Res Mol Brain Res 1998, 61:203-206.
37. Boutillier A.L., Trinh E., Loeffler J.P. Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis. J Neurochem 2003, 84:814-828.
38. Langley B., D'Annibale M.A., Suh K., Ayoub I., Tolhurst A., Bastan B., et al. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. J Neurosci 2008, 28:163-176.
39. Morrison B.E., Majdzadeh N., Zhang X., Lyles A., Bassel-Duby R., Olson E.N., et al. Neuroprotection by histone deacetylase-related protein. Mol Cell Biol 2006, 26:3550-3564.
40. Kazantsev A., Preisinger E., Dranovsky A., Goldgaber D., Housman D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc Natl Acad Sci USA 1999, 96:11404-11409.
41. McCampbell A., Taylor J.P., Taye A.A., Robitschek J., Li M., Walcott J., et al. CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 2000, 9:2197-2202.
42. Steffan J.S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.Z., Gohler H., et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 2000, 97:6763-6768.
43. McCampbell A., Taye A.A., Whitty L., Penney E., Steffan J.S., Fischbeck K.H. Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc Natl Acad Sci USA 2001, 98:15179-15184.
44. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., Apostol B.L., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
45. Sugars K.L., Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet 2003, 19:233-238.
46. Nucifora F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001, 291:2423-2428.
47. Parker J.A., Arango M., Abderrahmane S., Lambert E., Tourette C., Catoire H., et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 2005, 37:349-350.
48. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003, 23:9418-9427.
49. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003, 100:2041-2046.
50. Gardian G., Browne S.E., Choi D.K., Klivenyi P., Gregorio J., Kubilus J.K., et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 2005, 280:556-563.
51. Thomas E.A., Coppola G., Desplats P.A., Tang B., Soragni E., Burnett R., et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci USA 2008, 105:15564-15569.
52. Ryu H., Smith K., Camelo S.I., Carreras I., Lee J., Iglesias A.H., et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 2005, 93:1087-1098.
53. Echaniz-Laguna A., Bousiges O., Loeffler J.P., Boutillier A.L. Histone deacetylase inhibitors: therapeutic agents and research tools for deciphering motor neuron diseases. Curr Med Chem 2008, 15:1263-1273.
54. Cui S.S., Yang C.P., Bowen R.C., Bai O., Li X.M., Jiang W., et al. Valproic acid enhances axonal regeneration and recovery of motor function after sciatic nerve axotomy in adult rats. Brain Res 2003, 975:229-236.
55. Araki T., Sasaki Y., Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004, 305:1010-1013.
56. Suzuki K., Koike T. Mammalian Sir2-related protein (SIRT) 2-mediated modulation of resistance to axonal degeneration in slow Wallerian degeneration mice: a crucial role of tubulin deacetylation. Neuroscience 2007, 147:599-612.
57. Kaneko S., Wang J., Kaneko M., Yiu G., Hurrell J.M., Chitnis T., et al. Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J Neurosci 2006, 26:9794-9804.
58. Dompierre J.P., Godin J.D., Charrin B.C., Cordelieres F.P., King S.J., Humbert S., et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 2007, 27:3571-3583.
59. Pandey U.B., Nie Z., Batlevi Y., McCray B.A., Ritson G.P., Nedelsky N.B., et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007, 447:859-863.
60. Iwata A., Riley B.E., Johnston J.A., Kopito R.R. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 2005, 280:40282-40292.
61. Kawaguchi Y., Kovacs J.J., McLaurin A., Vance J.M., Ito A., Yao T.P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003, 115:727-738.
62. Outeiro T.F., Kontopoulos E., Altmann S.M., Kufareva I., Strathearn K.E., Amore A.M., et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007, 317:516-519.
63. Kim J., Shen S., Dietz K., He Y., Howell O., Reynolds R., et al. Nuclear export of HDAC1 is induced by pathological conditions and is essential for the onset of axonal damage. Nat Neurosci 2010, 13:180-189.
64. Pearce E.L., Shen H. Making sense of inflammation, epigenetics, and memory CD8+ T-cell differentiation in the context of infection. Immunol Rev 2006, 211:197-202.
65. Gray S.G., Dangond F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 2006, 1:67-75.
66. Reddy P., Maeda Y., Hotary K., Liu C., Reznikov L.L., Dinarello C.A., et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 2004, 101:3921-3926.
67. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007, 13:1299-1307.
68. Moreira J.M., Scheipers P., Sorensen P. The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 2003, 3:30.
69. Camelo S., Iglesias A.H., Hwang D., Due B., Ryu H., Smith K., et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 2005, 164:10-21.
70. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69.
71. Faraco G., Pittelli M., Cavone L., Fossati S., Porcu M., Mascagni P., et al. Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol Dis 2009, 36:269-279.
72. Suuronen T., Huuskonen J., Pihlaja R., Kyrylenko S., Salminen A. Regulation of microglial inflammatory response by histone deacetylase inhibitors. J Neurochem 2003, 87:407-416.
73. Chen L., Fischle W., Verdin E., Greene W.C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 2001, 293:1653-1657.
74. Ashburner B.P., Westerheide S.D., Baldwin A.S. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 2001, 21:7065-7077.
75. Chen J., Zhou Y., Mueller-Steiner S., Chen L.F., Kwon H., Yi S., et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005, 280:40364-40374.
76. Chen P.S., Wang C.C., Bortner C.D., Peng G.S., Wu X., Pang H., et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007, 149:203-212.
77. Shein N.A., Grigoriadis N., Alexandrovich A.G., Simeonidou C., Lourbopoulos A., Polyzoidou E., et al. Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J 2009, 23:4266-4275.
78. Gensert J.M., Baranova O.V., Weinstein D.E., Ratan R.R., CD81 a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells. Neurobiol Dis 2007, 26:671-680.
79. Eyupoglu I.Y., Hahnen E., Trankle C., Savaskan N.E., Siebzehnrubl F.A., Buslei R., et al. Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Mol Cancer Ther 2006, 5:1248-1255.
80. Chen P.S., Peng G.S., Li G., Yang S., Wu X., Wang C.C., et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006, 11:1116-1125.
81. Wu J.Y., Niu F.N., Huang R., Xu Y. Enhancement of glutamate uptake in 1-methyl-4-phenylpyridinium-treated astrocytes by trichostatin A. Neuroreport 2008, 19:1209-1212.
82. Wu H.M., Tzeng N.S., Qian L., Wei S.J., Hu X., Chen S.H., et al. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology 2009, 34:2344-2357.
83. Dutta R., Trapp B.D. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007, 68:S43-S54. [discussion S22-31].
84. Marin-Husstege M., Muggironi M., Liu A., Casaccia-Bonnefil P. Histone deacetylase activity is necessary for oligodendrocyte lineage progression. J Neurosci 2002, 22:10333-10345.
85. Shen S., Li J., Casaccia-Bonnefil P. Histone modifications affect timing of oligodendrocyte progenitor differentiation in the developing rat brain. J Cell Biol 2005, 169:577-589.
86. Shen S., Liu A., Li J., Wolubah C., Casaccia-Bonnefil P. Epigenetic memory loss in aging oligodendrocytes in the corpus callosum. Neurobiol Aging 2008, 29:452-463.
87. Liu H., Hu Q., D'Ercole A.J., Ye P. Histone deacetylase 11 regulates oligodendrocyte-specific gene expression and cell development in OL-1 oligodendroglia cells. Glia 2009, 57:1-12.
88. Shen S., Sandoval J., Swiss V.A., Li J., Dupree J., Franklin R.J., et al. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat Neurosci 2008, 11:1024-1034.
89. Khalili K., White M.K. Human demyelinating disease and the polyomavirus JCV. Mult Scler 2006, 12:133-142.
90. Kim S.Y., Woo M.S., Kim W.K., Choi E.C., Henson J.W., Kim H.S. Glial cell-specific regulation of the JC virus early promoter by histone deacetylase inhibitors. J Virol 2003, 77:3394-3401.
91. Liu A., Muggironi M., Marin-Husstege M., Casaccia-Bonnefil P. Oligodendrocyte process outgrowth in vitro is modulated by epigenetic regulation of cytoskeletal severing proteins. Glia 2003, 44:264-274.